The ups and downs that have marked IntraBiotics Pharmaceuticals Inc.’s recent history continued, as the company said the first glimpse of unblinded data from its Phase III iseganan hydrochloride oral solution showed the product fared poorly against placebo in primary and secondary endpoints, sending its stock crashing 69.5 percent. (BioWorld Today) Read More
